1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,287 | 0,346 | 12.05. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.05. | Invitation to the Presentation of Cantargia's Interim Report for Q1 2026 | 231 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 6, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for Q1 2026 on Tuesday, May 19, 2026, at 07:00 a.m. CEST.In conjunction... ► Artikel lesen | |
| 27.04. | Cantargia Announces Early Results from Trial of Nadunolimab in MDS and AML | 297 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 27, 2026 / Cantargia AB (Nasdaq Stockholm:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced early... ► Artikel lesen | |
| 17.04. | Cantargia Announces AACR 2026 Presentation of Study Design and Supportive Pre-Clinical Data for Investigator-Initiated Nadunolimab Study in MSS CRC | 360 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia (STO:CANTA) - Cantargia AB (Publ) (Nasdaq Stockholm:CANTA) today reported that the rationale and study design of the phase 1b/2 clinical trial... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 17.04. | Cantargia Publishes Annual Report 2025 | 219 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that the annual report for 2025 has been published. The Annual Report is attached to this press... ► Artikel lesen | |
| 17.04. | Notice of Annual General Meeting in Cantargia AB | 201 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ), reg. no. 556791-6019, are invited to the annual general meeting on Thursday, 21 May 2026... ► Artikel lesen | |
| 05.03. | Cantargia to Participate at Van Lanschot Kempen's Life Sciences Conference | 486 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 5, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargias management will participate in one-on-one meetings... ► Artikel lesen | |
| 23.02. | Cantargia to Participate in TD Cowen's Annual Healthcare Conference | 412 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 23, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargia's management will participate in and host 1-1 meetings... ► Artikel lesen | |
| 20.02. | Cantargia Publishes Full Year Report 2025 | 300 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 20, 2026 / Cantargia AB's (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) full year report for 2025 is now available on the company's web page www.cantargia.com/en/investors/financial-reports."Cantargia... ► Artikel lesen | |
| 06.02. | Invitation to the Presentation of Cantargia's Annual Results for 2025 | 335 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 6, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's annual results report for 2025 on Friday, February 20, 2026, at 07:00 a.m. CET.In... ► Artikel lesen | |
| 28.01. | Cantargia to Participate at Leerink Partners Global Healthcare Conference | 304 | ACCESS Newswire | LUND, SE / ACCESS Newswire / January 28, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargias management will participate in one-on-one... ► Artikel lesen | |
| 23.01. | Cantargia Reports First Patient Dosed in New US Investigator-Initiated Colorectal Cancer Study | 250 | ACCESS Newswire | LUND, SE / ACCESS Newswire / January 23, 2026 / Cantargia AB (Publ) (STO:CANTA) today reported that the first patient has been dosed in a Phase 1b/2 clinical trial investigating nadunolimab in combination... ► Artikel lesen | |
| 05.12.25 | Cantargia Provides Update on Overall Survival Data from TRIFOUR | 309 | ACCESS Newswire | LUND, SE / ACCESS Newswire / December 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (Publ) (NASDAQ:CANTA.ST) today announced an update on overall survival results from the Phase 1b/2 TRIFOUR study... ► Artikel lesen | |
| 19.11.25 | Cantargia Q3 2025: Erster Gewinn durch transformativen Otsuka-Deal | 7 | Investing.com Deutsch | ||
| 19.11.25 | Cantargia Q3 2025 slides: First-ever profit driven by transformational Otsuka deal | 7 | Investing.com | ||
| 19.11.25 | Earnings Call Transkript: Cantargia meldet im 3. Quartal 2025 erstmals Umsatzerlöse | 4 | Investing.com Deutsch | ||
| 19.11.25 | Cantargia Publishes Interim Report for January to September 2025 | 375 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 19, 2025 / Cantargia AB (publ) ("Cantargia") (STO:CANTA) issued its interim report for the period January until September 2025. The report is now available on the... ► Artikel lesen | |
| 12.11.25 | Cantargia Presents Nomination Committee Ahead of 2026 AGM | 339 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 12, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today provided notification that the Nomination Committee (NC) has been appointed... ► Artikel lesen | |
| 05.11.25 | Invitation to the Presentation of Cantargia's Interim Report January-September 2025 | 290 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for the first nine months of 2025 on Wednesday... ► Artikel lesen | |
| 23.10.25 | Cantargia to Participate in Upcoming Conferences | 347 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 23, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that management will participate in the following investor conferences.Stifel... ► Artikel lesen | |
| 02.10.25 | Cantargia Appoints Dr. Wolfram Dempke As Chief Medical Officer | 384 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 2, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm: CANTA) today announced the appointment of Wolfram Dempke, MD, PhD, MBA as Chief Medical... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,70 | +0,63 % | Ihre wichtigsten Termine: Spannende Updates von: Pfizer, PayPal, American Express, Cummins, SAP & Biontech | © Foto: Jeff Chiu/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:00... ► Artikel lesen | |
| EVOTEC | 5,080 | -2,31 % | Kursexplosion bei Evotec! Sommer-Rally bei Desert Gold? Rheinmetall-Aktie auf 2.000 EUR? | Kursexplosion bei Evotec. Nach positiven News aus einer Wirkstoffforschungskooperation kletterte die Aktie zwischenzeitlich um über 9 %. Damit setzt sich der Aufwärtstrend der vergangenen Wochen fort.... ► Artikel lesen | |
| QIAGEN | 28,800 | +2,27 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat die Einstufung für Qiagen nach endgültigen Quartalszahlen auf "Equal Weight" mit einem Kursziel von 38 US-Dollar belassen. Analyst... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 613,60 | +1,40 % | Mesoblast Aktie: Warum sich der Blick auf diesen Biotech-Player jetzt lohnt - und was Anleger von Merck, Regeneron & Co. lernen können | ||
| BRAIN BIOTECH | 3,230 | -3,58 % | BRAIN BIOTECH AG zeigt fundamentale Stärke | ||
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| CARDIOL THERAPEUTICS | 1,146 | +1,06 % | Cardiol Therapeutics Inc: Cardiol to publish phase II Maveric results in JAHA | ||
| CSL | 61,15 | -2,13 % | CSL's Big Write-Down Halves Broker Forecasts | ||
| BURCON NUTRASCIENCE | 1,210 | -3,20 % | Burcon NutraScience Corporation: Burcon Announces Appointment of New Director | Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) (the "Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| MANNKIND | 2,942 | +2,94 % | MannKind Reports First Quarter 2026 Financial Results and Provides Business Update | Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025Built out launch infrastructure and aligned field-based teams for upcoming launchesSettlement of senior convertible notes of $36.3M Program... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,700 | -2,53 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,378 | +3,45 % | Oxford Nanopore Tech - Director/PDMR Shareholding | ||
| ADAPTIMMUNE THERAPEUTICS | 0,007 | -50,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| CODEXIS | 2,132 | -4,57 % | Codexis reiterates $72M-$76M 2026 revenue outlook while targeting 0.5 kilogram ECO Synthesis scale by year-end | ||
| CORMEDIX | 6,590 | +1,38 % | CorMedix, Inc.: CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026 |
CANTARGIA AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,48 % bei einem Aktienkurs von 0,291 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.